[Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 950-953

  Guérin, Brigitte ^a   Dumulon Perreault, Véronique ^a   Tremblay, Marie Claude ^a   Ait Mohand, Samia ^a   Fournier, Patrick ^a   Dubuc, Céléna ^a   Authier, Simon ^a   Bénard, François ^b  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

DOTA BVD15 analogs; NPY1R; PET imaging

Indexed keywords

[LYSINE(1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID) 4 ]BVD15; NEUROPEPTIDE Y DERIVATIVE; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; TRACER; UNCLASSIFIED DRUG; DOTA4 COMPOUND; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y-Y1 RECEPTOR; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; BREAST CANCER; CONTROLLED STUDY; CROSS COUPLING REACTION; DRUG POTENCY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; POSITRON; POSITRON EMISSION TOMOGRAPHY; ANALOGS AND DERIVATIVES; BREAST TUMOR; CELL LINE; COMPARATIVE STUDY; DIAGNOSTIC USE; DRUG DESIGN; METABOLISM; SCINTISCANNING; SYNTHESIS; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; DRUG DESIGN; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; NEUROPEPTIDE Y; RADIOPHARMACEUTICALS; RECEPTORS, NEUROPEPTIDE Y;

EID: 74049095241     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.12.068     Document Type: Article

References (21)

1. Inui A. Mol. Med. Today 5 (1999) 79
2. Lin S., Boey D., and Herzog H. Neuropeptides 38 (2004) 189
3. Xu M., Urbanm J.H., Hill J.W., and Levine J.E. Endocrinology 141 (2000) 3319
4. Parker S.L., Carroll B.L., Kalra S.P., St-Pierre S., Fournier A., and Crowley W.R. Endocrinology 137 (1996) 2896
5. Reubi J.C., Gugger M., and Waser B. Eur. J. Nucl. Med. 29 (2002) 855
6. Reubi J.C., Gugger M., Waser B., and Schaer J.C. Cancer Res. 61 (2001) 4636
7. Korner M., Waser B., and Reubi J.C. Lab. Invest. 84 (2004) 71
8. Amlal H., Faroqui S., Balasubramaniam A., and Sheriff S. Cancer Res. 66 (2006) 3706
9. Ruscica M., Dozio E., Boghossian S., Bovo G., Martos Riaño V., Motta M., and Magni P. Endocrinology 147 (2006) 1466
10. Korner M., Waser B., and Reubi J.C. Clin. Cancer Res. 10 (2004) 8426
11. Korner M., Waser B., and Reubi J.C. Int. J. Cancer 115 (2005) 734
12. Langer M., La Bella R., Garcia-Garayoa E., and Beck-Sickinger A.G. Bioconjugate Chem. 12 (2001) 1028
13. Zwanziger D., Ullah Khan I., Neudorf I., Seiger S., Lehmann L., Friebe M., Dinkelborg L., and Beck-Sickinger A.G. Bioconjugate Chem. 19 (2008) 1430
14. Daniels A.J., Mathews J.E., Slepetis R.J., Jansen M., Viveros O.H., and Tadepalli A. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9067
15. Jois S.D.S., and Balasubramaniam A. Peptides 24 (2003) 1035
16. Balasubramaniam A., Dhawan V.C., Mullins D.E., Chance W.T., Sheriff S., Guzzi M., Prabhakaran M., and Parker E.M. J. Med. Chem. 44 (2001) 1479
17. Koglin N., Zorn C., Beumer R., Cabrele C., Bubert C., Sewald N., Reiser O., and Beck-Sickinger A.G. Angew. Chem., Int. Ed. 42 (2003) 202
18. Chen X., Park R., Hou Y., Tohme M., Shahinian A.H., Bading J.R., and Conti P.S. J. Nucl. Med. 45 (2004) 1390
19. 2 in 0.1 ammonium acetate buffer, pH 5.5.
20. Dumont Y., Gaudreau P., Mazzuferi M., Langlois D., Chabot J.-G., Fournier A., Simonato M., and Quirion R. Br. J. Pharmacol. 146 (2005) 1069
21. 125I-PP.